Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Further trials sought for MRI (magnetic resonance imaging) contrast agent:

This article was originally published in Clinica

Executive Summary

EPIX Medical and Mallinckrodt will seek US approval to begin Phase III trials of an injectable MRI contrast agent for detecting peripheral vascular disease following successful Phase II studies. The agent, called MS-325, was compared with the current X-ray angiography procedure and had an 82% accuracy in identifying clinically significant stenosis. EPIX, based in Cambridge, Massachusetts, said the agent could provide a minimally invasive way of visualising the peripheral vasculature early on in a patient's assessment and reduce the serious side-effects and complications associated with the highly invasive X-ray angiography procedure.

You may also be interested in...

Accord Backed In EU For Trastuzumab And Apixaban

Accord Healthcare is looking to breaking into the crowded market for biosimilar trastuzumab in the EU, after partner Henlius’ application was backed by the EMA’s CHMP. Meanwhile, a recommendation for a generic to the Eliquis anticoagulant was also forthcoming from the committee.

‘Not Yet But Shortly’: EU Remdesivir Filing

The European Medicines Agency has provided an update on the status of its review of Gilead’s investigational antiviral in the treatment of COVID-19.

Sandoz Study Highlights Saving Potential Of Pegfilgrastim Biosimilar

Sandoz has published the results of two studies involving the company’s pegfilgrastim biosimilar and glatiramer acetate generic. For the former, Sandoz observed cost savings could run eventually to tens of millions of dollars per year with patient conversion and expanded access.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts